
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 06, 2023, titled "Zydus receives USFDA approval for ZITUVIMETTM to treat adult patients with type 2 diabetes mellitus".
Filed with NSE ·

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 06, 2023, titled "Zydus receives USFDA approval for ZITUVIMETTM to treat adult patients with type 2 diabetes mellitus".
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences